Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

• To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Collaborator: Chugai Pharmaceutical
• Treatments: Letrozole

Criteria

Inclusion Criteria:

• Patients which participated in double blind study

Exclusion Criteria:

• Patients with intolerable toxicity.

• Patients which confirmed progressive disease during double blind study.

• Patients which have received concurrent anti-cancer therapy during double blind study.